CN Patent

CN116478211B — 一种新型cgrp受体拮抗剂及其用途

Assigned to Shijiazhuang Dikaiwei Pharmaceutical Technology Co ltd · Expires 2023-10-24 · 3y expired

What this patent protects

本发明公开CGRP受体拮抗剂及其用途，所述的CGRP受体拮抗剂具有式I‑0所示的结构，或式I‑0结构的药学上可接受的盐、及其盐的异构体。本发明还提供了式I‑0的化合物在制备用于预防和/或治疗哮喘病等相关呼吸道疾病中的应用。

USPTO Abstract

本发明公开CGRP受体拮抗剂及其用途，所述的CGRP受体拮抗剂具有式I‑0所示的结构，或式I‑0结构的药学上可接受的盐、及其盐的异构体。本发明还提供了式I‑0的化合物在制备用于预防和/或治疗哮喘病等相关呼吸道疾病中的应用。

Drugs covered by this patent

Patent Metadata

Patent number
CN116478211B
Jurisdiction
CN
Classification
—
Expires
2023-10-24
Drug substance claim
No
Drug product claim
No
Assignee
Shijiazhuang Dikaiwei Pharmaceutical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.